<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546623</url>
  </required_header>
  <id_info>
    <org_study_id>TAP-144-SR(6M)IP/CPH-002</org_study_id>
    <secondary_id>U1111-1128-6861</secondary_id>
    <secondary_id>JapicCTI-121763</secondary_id>
    <nct_id>NCT01546623</nct_id>
  </id_info>
  <brief_title>A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy</brief_title>
  <official_title>A Phase 3, Multi-center, Randomized, Open-label, Parallel-group, Comparative Study of TAP-144-SR (3M) to Evaluate Hormone Dynamics, Pharmacokinetics, Safety and Efficacy of TAP-144-SR (6M) 22.5 mg Subcutaneous Injection for 48 Weeks in Prostate Cancer Patients Previously Treated With Hormonal Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate hormone dynamics, pharmacokinetics, safety, and
      efficacy of TAP-144-SR(6M) against TAP-144-SR(3M) in prostate cancer patients previously
      treated with hormonal therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Suppression of Serum Testosterone to Castrate Level</measure>
    <time_frame>From the start of study drug administration through Week 48</time_frame>
    <description>Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Course of Changes in Serum Testosterone</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Changes in Serum Luteinizing Hormone (LH)</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Changes in Serum Follicle-stimulating Hormone (FSH)</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Change Rate in Serum PSA (FAS)</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>Evaluation according to the &quot;Criteria for therapeutic effect&quot; from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen [PSA])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Maximum Rate of Change in PSA Suppression (FAS)</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>Evaluation according to the &quot;Criteria for therapeutic effect&quot; from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Progression by PSA (FAS)</measure>
    <time_frame>From baseline to Week 48</time_frame>
    <description>Evaluation according to the &quot;Criteria for therapeutic effect&quot; from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft Tissue Response</measure>
    <time_frame>At week 48</time_frame>
    <description>Assessment in accordance with the &quot;criteria for therapeutic effect&quot; from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Lesion Response</measure>
    <time_frame>At Week 48</time_frame>
    <description>Partially revised assessment based on the &quot;criteria for therapeutic effect&quot; from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Unchanged TAP-144 Level</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>At 1 hour, week 24, and week 48 after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>TAP-144-SR(6M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP-144-SR(3M)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAP-144-SR(6M)</intervention_name>
    <arm_group_label>TAP-144-SR(6M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAP-144-SR(3M)</intervention_name>
    <arm_group_label>TAP-144-SR(3M)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The participant has histopathologically confirmed prostate cancer in Japanese.

          2. The participant has prostate cancer in the clinical stages of T1b-T4, N-any and M-any
             by TNM classification on clinical diagnosis at the time of diagnosis.

          3. The participant has ECOG performance status of grades 0, 1, or 2 at screening.

          4. The participant with PSA level which has not increased 25 % or greater and 2 ng/mL or
             more from the nadir at the measurement points 4 weeks or longer apart within the
             screening period of 12 weeks.

          5. Patients who receive the marketed product for 3 months (LEUPLIN SR FOR INJECTION KIT
             11.25) at screening

          6. Patients who have received the marketed products, TAP-144-SR (1M) and TAP-144-SR (3M),
             for 24-96 weeks in total at the scheduled starting date of the study drug, but not
             including administration period treated as neoadjuvant therapy for prostatectomy
             and/or radiation therapy

          7. Patients who have continued the nonsteroidal antiandrogen for longer than 12 weeks at
             the scheduled starting date of the study drug, if a nonsteroidal antiandrogen is
             concomitantly administered

          8. The participant with a serum testosterone level at screening &lt; 100ng/dL

          9. The participant meets the following criteria of renal, bone-marrow and hepatic
             functions on the laboratory test results at screening:

        （1） Renal function: serum creatinine level&lt; 1.5 times the upper limit of normal (ULN) （2）
        Bone-marrow function: white blood count ≥ 3,500/ mm3, platelet count ≥ 100,000/L,
        hemoglobin ≥ 10.0g/dL （3） Hepatic function: AST(GOT), ALT(GPT), ALP and total bilirubin ≤
        2.5 times the ULN 10. The participant's life expectancy is at least 24 months at informed
        consent.

        Exclusion Criteria:

          1. The participant has active multiple primary cancers, (synchronous multiple primary
             cancer or metachronous multiple primary cancer with the disease-free survival ≤ 5
             years)

          2. The participant has received surgical castration.

          3. The participant has ever received LHRH agonists other than commercially available
             1-month or 3-month depot of leuprolide acetate.

          4. The participant has ever received LHRH antagonists.

          5. Patients who have previously received estrogen preparations or corticosteroids for
             prostate cancer

          6. Patients who have previously received chemotherapy for prostate cancer

          7. Patients who are receiving or received the marketed product for 3 months (LEUPLIN SR
             FOR INJECTION KIT 11.25) or the marketed products for 1 month (LEUPLIN FOR INJECTION
             3.75 and KIT 3.75) as an adjuvant therapy after prostatectomy and/or radiotherapy

          8. Patients who are receiving or received the marketed product for 3 months (LEUPLIN SR
             FOR INJECTION KIT 11.25) for intermittent androgen deprivation therapy

          9. Patients who received the following drugs within 24 weeks (168 days) after starting
             the study drug: Steroidal antiandrogens, type II 5α-reductase inhibitors

         10. The participant received any of the following within 16 weeks (112 days) prior to
             study enrollment:

        （1） Radiotherapy. As for I-125 brachytherapy, within 35 weeks (245 days) prior to study
        enrollment.

        （2） Prostatectomy （3） Experimental therapy including high-intensity focused ultrasound
        therapy (HIFU), immunotherapy, and gene therapy 11. Patients who received the following
        drugs within 4 weeks (28 days) before starting the study drug: Testosterones,
        ketoconazole（except for external preparations）, spironolactone, corticosteroids (excluding
        their inhalants and external preparations), and Chinese medicines and dietary supplements
        containing saw palmetto 12. Patients whose QTcF interval exceeded 460 msec on the 12-lead
        electrocardiogram at screening 13. The participant has a history of hypersensitivity to
        synthetic LHRH, LHRH derivative or any component of the study drug.

        14. The participant has central nervous system metastasis which requires treatment or which
        is symptomatic.

        15. The participant already has a history or has a complication or may have renal disorder
        caused by spinal cord compression or ureteric obstruction.

        16. The participant has a history of serious drug allergic reaction/hypersensitivity 17.
        The participant has a history of, or has been diagnosed with thromboembolism including
        myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism, or
        cardiac failure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nigata-shi</city>
        <state>Nigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ageo-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-adachi-gun</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <results_first_submitted>April 2, 2015</results_first_submitted>
  <results_first_submitted_qc>June 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2015</results_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 23 investigative sites in Japan from 11 April 2012 to 04 April 2014.</recruitment_details>
      <pre_assignment_details>Prostate cancer patients previously treated with hormonal therapy were enrolled in 1 of 2 treatment groups. Two patients withdrew from the period between randomization and starting study drugs (1 in TAP-144-SR(6M) arm and 1 in TAP-144-SR(3M) arm).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAP-144-SR(6M)</title>
          <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>TAP-144-SR(3M)</title>
          <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>High Prostate specific antigen</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The population included all participants who were randomized to treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>TAP-144-SR(6M)</title>
          <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>TAP-144-SR(3M)</title>
          <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="6.32"/>
                    <measurement group_id="B2" value="72.6" spread="6.49"/>
                    <measurement group_id="B3" value="73.0" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.03" spread="8.689"/>
                    <measurement group_id="B2" value="65.83" spread="8.098"/>
                    <measurement group_id="B3" value="64.92" spread="8.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.61" spread="2.731"/>
                    <measurement group_id="B2" value="24.32" spread="2.769"/>
                    <measurement group_id="B3" value="23.96" spread="2.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>Gleason score is a score used in prostate cancer grading. Prostate cancer staging is the process by which physicians categorize the risk of cancer having spread beyond the prostate, or equivalently, the probability of being cured with local therapies such as surgery or radiation. Gleason score are often grouped into four stages (I–IV) of prostate cancer. Gleason scores range from 2 to 10, with 2 representing the most well-differentiated tumors and 10 the least-differentiated tumors.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0.0"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0.0"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0.0"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" spread="2.4"/>
                    <measurement group_id="B2" value="2" spread="2.5"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="9.8"/>
                    <measurement group_id="B2" value="7" spread="8.8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="42.7"/>
                    <measurement group_id="B2" value="29" spread="36.3"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" spread="17.1"/>
                    <measurement group_id="B2" value="21" spread="26.3"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="24.4"/>
                    <measurement group_id="B2" value="21" spread="26.3"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="3.7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor-node-metastasis (TNM) classification at diagnosis: T</title>
          <description>Number of participants for whom TNM classification at diagnosis: T data is available in the TAP-144-SR(3M) treatment arm is 79, respectively.
The categories of T is ranged from T1 (better) to T4 (worse). Tx represents &quot;tumor cannot be evaluated&quot; and T0 represents &quot;no signs of tumor.&quot;</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0.0"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="20.7"/>
                    <measurement group_id="B2" value="16" spread="20.3"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="39.0"/>
                    <measurement group_id="B2" value="24" spread="30.4"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="35.4"/>
                    <measurement group_id="B2" value="33" spread="41.8"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="4.9"/>
                    <measurement group_id="B2" value="6" spread="7.6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0.0"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM classification at diagnosis: N</title>
          <description>Number of participants for whom TNM classification at diagnosis: N data is available in the TAP-144-SR(3M) treatment arm is 79, respectively. The categories of N is represented by Nx (lymph nodes cannot be evaluated), N0 (tumor cells absent from regional lymph nodes), and N1 (regional lymph node metastasis present).</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>N0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM classification at diagnosis: M</title>
          <description>Number of participants for whom TNM classification at diagnosis: M data is available in the TAP-144-SR(3M) treatment arm is 79, respectively. The categories of M is represented by M0 (no distant metastasis), and M1 (metastasis to distant organs (beyond regional lymph nodes).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>M0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Period between date of first dianosis and date of informed consent</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.653" spread="2.0866"/>
                    <measurement group_id="B2" value="1.748" spread="2.0410"/>
                    <measurement group_id="B3" value="1.700" spread="2.0583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Period between first dose dates of leuproride acetate (over-the-counter) and the study drug</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.328" spread="20.0833"/>
                    <measurement group_id="B2" value="46.595" spread="20.8584"/>
                    <measurement group_id="B3" value="46.460" spread="20.4056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Number of participants for whom ECOG Performance Status data is available in Baseline Characteristics is 81 and 79 in each treatment arm, respectively. The categories of ECOG Performance Status is represented from 0 (Fully active, better) to 4 (Completely disabled, worse).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Suppression of Serum Testosterone to Castrate Level</title>
        <description>Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)</description>
        <time_frame>From the start of study drug administration through Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of study drug) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Suppression of Serum Testosterone to Castrate Level</title>
          <description>Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)</description>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of study drug) was used.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants maintained</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who did not maintain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Changes in Serum Testosterone</title>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of Changes in Serum Testosterone</title>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0" upper_limit="33"/>
                    <measurement group_id="O2" value="7.0" lower_limit="0" upper_limit="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0" upper_limit="33"/>
                    <measurement group_id="O2" value="7.0" lower_limit="0" upper_limit="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="0" upper_limit="53"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="41"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="45"/>
                    <measurement group_id="O2" value="7.5" lower_limit="0" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0" upper_limit="43"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0" upper_limit="30"/>
                    <measurement group_id="O2" value="5.5" lower_limit="0" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0" upper_limit="36"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="0" upper_limit="41"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O2" value="7.0" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0" upper_limit="39"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O2" value="8.0" lower_limit="0" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="0" upper_limit="42"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Changes in Serum Luteinizing Hormone (LH)</title>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of Changes in Serum Luteinizing Hormone (LH)</title>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="1.44"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.160" lower_limit="0.00" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.220" lower_limit="0.00" upper_limit="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" lower_limit="0.00" upper_limit="0.68"/>
                    <measurement group_id="O2" value="0.150" lower_limit="0.00" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.120" lower_limit="0.00" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.00" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.00" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.38"/>
                    <measurement group_id="O2" value="0.055" lower_limit="0.00" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.00" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="1.38"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" lower_limit="0.00" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.185" lower_limit="0.00" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.170" lower_limit="0.00" upper_limit="0.84"/>
                    <measurement group_id="O2" value="0.130" lower_limit="0.00" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" lower_limit="0.00" upper_limit="0.35"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.31"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="0.00" upper_limit="0.42"/>
                    <measurement group_id="O2" value="0.000" lower_limit="0.00" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Changes in Serum Follicle-stimulating Hormone (FSH)</title>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of Changes in Serum Follicle-stimulating Hormone (FSH)</title>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.120" lower_limit="1.93" upper_limit="13.31"/>
                    <measurement group_id="O2" value="4.780" lower_limit="2.02" upper_limit="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.430" lower_limit="1.87" upper_limit="15.52"/>
                    <measurement group_id="O2" value="4.810" lower_limit="1.77" upper_limit="17.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.890" lower_limit="1.99" upper_limit="13.12"/>
                    <measurement group_id="O2" value="4.710" lower_limit="1.81" upper_limit="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.625" lower_limit="1.72" upper_limit="14.11"/>
                    <measurement group_id="O2" value="4.950" lower_limit="1.49" upper_limit="16.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.225" lower_limit="1.90" upper_limit="13.75"/>
                    <measurement group_id="O2" value="5.240" lower_limit="1.79" upper_limit="17.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.340" lower_limit="2.24" upper_limit="14.04"/>
                    <measurement group_id="O2" value="5.110" lower_limit="1.86" upper_limit="15.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.300" lower_limit="2.07" upper_limit="13.87"/>
                    <measurement group_id="O2" value="5.370" lower_limit="1.81" upper_limit="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.030" lower_limit="1.65" upper_limit="12.21"/>
                    <measurement group_id="O2" value="5.260" lower_limit="1.91" upper_limit="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.990" lower_limit="1.97" upper_limit="13.45"/>
                    <measurement group_id="O2" value="5.150" lower_limit="2.12" upper_limit="16.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.210" lower_limit="2.16" upper_limit="12.92"/>
                    <measurement group_id="O2" value="4.970" lower_limit="1.84" upper_limit="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.010" lower_limit="2.34" upper_limit="13.14"/>
                    <measurement group_id="O2" value="5.020" lower_limit="1.96" upper_limit="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.060" lower_limit="2.31" upper_limit="13.38"/>
                    <measurement group_id="O2" value="5.070" lower_limit="2.05" upper_limit="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.210" lower_limit="2.32" upper_limit="13.20"/>
                    <measurement group_id="O2" value="5.030" lower_limit="2.08" upper_limit="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.585" lower_limit="2.01" upper_limit="13.00"/>
                    <measurement group_id="O2" value="4.970" lower_limit="2.09" upper_limit="14.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.100" lower_limit="1.80" upper_limit="14.85"/>
                    <measurement group_id="O2" value="4.910" lower_limit="2.05" upper_limit="13.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.150" lower_limit="1.69" upper_limit="12.90"/>
                    <measurement group_id="O2" value="4.990" lower_limit="2.17" upper_limit="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.110" lower_limit="1.44" upper_limit="11.69"/>
                    <measurement group_id="O2" value="4.820" lower_limit="2.18" upper_limit="14.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Change Rate in Serum PSA (FAS)</title>
        <description>Evaluation according to the “Criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen [PSA])</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course of Change Rate in Serum PSA (FAS)</title>
          <description>Evaluation according to the “Criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen [PSA])</description>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.930" lower_limit="-100.00" upper_limit="181.82"/>
                    <measurement group_id="O2" value="-10.000" lower_limit="-100.00" upper_limit="122.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.255" lower_limit="-100.00" upper_limit="190.06"/>
                    <measurement group_id="O2" value="-15.880" lower_limit="-100.00" upper_limit="184.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.810" lower_limit="-100.00" upper_limit="360.84"/>
                    <measurement group_id="O2" value="-21.130" lower_limit="-100.00" upper_limit="754.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.720" lower_limit="-100.00" upper_limit="634.69"/>
                    <measurement group_id="O2" value="-20.650" lower_limit="-100.00" upper_limit="1866.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.740" lower_limit="-100.00" upper_limit="932.65"/>
                    <measurement group_id="O2" value="-39.970" lower_limit="-100.00" upper_limit="3718.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.270" lower_limit="-100.00" upper_limit="2002.04"/>
                    <measurement group_id="O2" value="-31.110" lower_limit="-100.00" upper_limit="9900.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.705" lower_limit="-100.00" upper_limit="2920.41"/>
                    <measurement group_id="O2" value="-45.875" lower_limit="-100.00" upper_limit="15354.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.690" lower_limit="-100.00" upper_limit="7389.80"/>
                    <measurement group_id="O2" value="-40.745" lower_limit="-100.00" upper_limit="21051.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.710" lower_limit="-100.00" upper_limit="9675.51"/>
                    <measurement group_id="O2" value="-50.520" lower_limit="-100.00" upper_limit="23506.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.610" lower_limit="-100.00" upper_limit="5348.98"/>
                    <measurement group_id="O2" value="-58.520" lower_limit="-100.00" upper_limit="21627.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.105" lower_limit="-100.00" upper_limit="6859.18"/>
                    <measurement group_id="O2" value="-54.585" lower_limit="-100.00" upper_limit="24506.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.900" lower_limit="-100.00" upper_limit="6818.37"/>
                    <measurement group_id="O2" value="-59.400" lower_limit="-100.00" upper_limit="22839.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Maximum Rate of Change in PSA Suppression (FAS)</title>
        <description>Evaluation according to the “Criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Rate of Change in PSA Suppression (FAS)</title>
          <description>Evaluation according to the “Criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)</description>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.225" lower_limit="-100.00" upper_limit="108.73"/>
                    <measurement group_id="O2" value="-67.030" lower_limit="-100.00" upper_limit="75.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Progression by PSA (FAS)</title>
        <description>Evaluation according to the “Criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)</description>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Progression by PSA (FAS)</title>
          <description>Evaluation according to the “Criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)</description>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence of disesase progression: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of disesase progression: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soft Tissue Response</title>
        <description>Assessment in accordance with the “criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>At week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Soft Tissue Response</title>
          <description>Assessment in accordance with the “criteria for therapeutic effect” from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1"/>
                    <measurement group_id="O2" value="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Lesion Response</title>
        <description>Partially revised assessment based on the “criteria for therapeutic effect” from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression</description>
        <time_frame>At Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Lesion Response</title>
          <description>Partially revised assessment based on the “criteria for therapeutic effect” from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression</description>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence of disesase progression: New lesions ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of disesase progression: New lesions &lt; 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Unchanged TAP-144 Level</title>
        <time_frame>From baseline to Week 48</time_frame>
        <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Unchanged TAP-144 Level</title>
          <population>Full analysis set participants (all randomized participants who received at least 1 dose of open-label study drug) with both Baseline and a post-baseline value; last observation carried forward was used.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07113" spread="0.043808"/>
                    <measurement group_id="O2" value="0.06188" spread="0.035339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1304" spread="0.16388"/>
                    <measurement group_id="O2" value="0.1869" spread="0.077198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3085" spread="0.30523"/>
                    <measurement group_id="O2" value="0.1335" spread="0.083060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8845" spread="0.52695"/>
                    <measurement group_id="O2" value="0.1132" spread="0.12110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1792" spread="0.10354"/>
                    <measurement group_id="O2" value="0.08374" spread="0.041078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1256" spread="0.068860"/>
                    <measurement group_id="O2" value="0.08039" spread="0.056305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1024" spread="0.093951"/>
                    <measurement group_id="O2" value="0.1220" spread="0.067137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06957" spread="0.053682"/>
                    <measurement group_id="O2" value="0.08450" spread="0.039532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05167" spread="0.043221"/>
                    <measurement group_id="O2" value="0.07437" spread="0.045186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1353" spread="0.29809"/>
                    <measurement group_id="O2" value="0.1978" spread="0.083286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4318" spread="0.63101"/>
                    <measurement group_id="O2" value="0.1418" spread="0.087312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7622" spread="0.42483"/>
                    <measurement group_id="O2" value="0.1067" spread="0.054505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1524" spread="0.098308"/>
                    <measurement group_id="O2" value="0.08236" spread="0.046180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1091" spread="0.057582"/>
                    <measurement group_id="O2" value="0.08407" spread="0.075147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09118" spread="0.065771"/>
                    <measurement group_id="O2" value="0.1086" spread="0.051455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06958" spread="0.055624"/>
                    <measurement group_id="O2" value="0.08639" spread="0.051923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04596" spread="0.030006"/>
                    <measurement group_id="O2" value="0.07945" spread="0.066980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-lead ECG</title>
        <time_frame>At 1 hour, week 24, and week 48 after administration</time_frame>
        <population>Safety evaluation was conducted in the safety analysis set (SAS), which includes all 160 patients who received the study drug [TAP-144-SR (&amp;M) group: 81 patients, TAP-144-SR (3M) group: 79 patients</population>
        <group_list>
          <group group_id="O1">
            <title>TAP-144-SR(6M)</title>
            <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>TAP-144-SR(3M)</title>
            <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>12-lead ECG</title>
          <population>Safety evaluation was conducted in the safety analysis set (SAS), which includes all 160 patients who received the study drug [TAP-144-SR (&amp;M) group: 81 patients, TAP-144-SR (3M) group: 79 patients</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcF interval measurement at Basline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.0" spread="15.75"/>
                    <measurement group_id="O2" value="436.2" spread="15.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval measurement at 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422.2" spread="20.80"/>
                    <measurement group_id="O2" value="432.2" spread="21.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval measurement at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.0" spread="20.01"/>
                    <measurement group_id="O2" value="433.4" spread="18.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval measurement at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.1" spread="16.42"/>
                    <measurement group_id="O2" value="431.7" spread="16.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open-label study drug (up to 56 weeks).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TAP-144-SR(6M)</title>
          <description>TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>TAP-144-SR(3M)</title>
          <description>TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

